Another COVID-19 vaccine is right around the corner

Another COVID-19 vaccine is right around the corner

Late last week, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, highlighting that the single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints.

Due to this data, Johnson & Johnson’s vaccine looks as though it will become the third U.S. Covid-19 vaccine to enter the market. The data the company released last week showed that the vaccine is approximately 70% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination. 

The next step for Johnson & Johnson’s vaccine is for the company to file for U.S. Emergency Use Authorization in early February and they expect to have product available to ship immediately following authorization.

Read the full article here